{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nervous+System+Cancer&page=80",
    "query": {
      "condition": "Nervous System Cancer",
      "page": 80
    },
    "page_size": 10
  },
  "pagination": {
    "page": 80,
    "page_size": 10,
    "total_count": 3924,
    "total_pages": 393,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nervous+System+Cancer&page=81&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nervous+System+Cancer&page=79&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T05:21:07.130Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01439919",
      "title": "A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Breakthrough Cancer Pain"
      ],
      "interventions": [
        {
          "name": "SSR411298",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for SSR411298)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-01",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2013-03-21",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 2,
      "location_summary": "Flat Rock, North Carolina • Canton, Ohio",
      "locations": [
        {
          "city": "Flat Rock",
          "state": "North Carolina"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439919"
    },
    {
      "nct_id": "NCT00122044",
      "title": "Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dystonia"
      ],
      "interventions": [
        {
          "name": "trihexyphenidyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 35,
      "start_date": "2003-01",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2014-05-23",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Stanford, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00122044"
    },
    {
      "nct_id": "NCT00381797",
      "title": "Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Cerebral Anaplastic Astrocytoma",
        "Childhood Oligodendroglioma",
        "Childhood Spinal Cord Neoplasm",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "RADIATION"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 97,
      "start_date": "2006-08",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-11-28",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381797"
    },
    {
      "nct_id": "NCT03868423",
      "title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "ALK Fusion Protein Expression",
        "ALK Gene Amplification",
        "ALK Gene Mutation",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Metastatic Malignant Solid Neoplasm",
        "ROS1 Fusion Positive",
        "ROS1 Gene Amplification",
        "ROS1 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sameek Roychowdhury",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-03-20",
      "completion_date": "2021-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03868423"
    },
    {
      "nct_id": "NCT04042870",
      "title": "Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Joint Loosening Yoga",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "AshtaYoga, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 70 Years · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2018-09-04",
      "completion_date": "2018-10-19",
      "has_results": false,
      "last_update_posted_date": "2019-08-02",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04042870"
    },
    {
      "nct_id": "NCT00201903",
      "title": "The Roles of Tissue Factor in Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism",
        "Brain Tumors"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ontario Clinical Oncology Group (OCOG)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-01",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201903"
    },
    {
      "nct_id": "NCT01453283",
      "title": "Tabectedin to Treat Children and Adolescents With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "4 Years to 16 Years"
      },
      "enrollment_count": 12,
      "start_date": "2006-12-20",
      "completion_date": "2011-10-11",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453283"
    },
    {
      "nct_id": "NCT01190930",
      "title": "Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Adult B Lymphoblastic Lymphoma",
        "Ann Arbor Stage I B Lymphoblastic Lymphoma",
        "Ann Arbor Stage II B Lymphoblastic Lymphoma",
        "Childhood B Acute Lymphoblastic Leukemia",
        "Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",
        "Childhood B Lymphoblastic Lymphoma",
        "Down Syndrome",
        "Hypodiploid B Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Thioguanine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 9350,
      "start_date": "2010-08-11",
      "completion_date": "2026-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 213,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190930"
    },
    {
      "nct_id": "NCT01345136",
      "title": "Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 2",
        "Neuroma, Acoustic"
      ],
      "interventions": [
        {
          "name": "RAD001, everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2015-07-01",
      "completion_date": "2024-02-06",
      "has_results": false,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345136"
    },
    {
      "nct_id": "NCT00467844",
      "title": "Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cachexia"
      ],
      "interventions": [
        {
          "name": "GTx-024",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GTx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 159,
      "start_date": "2007-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-07-11",
      "last_synced_at": "2026-11-22T05:21:07.130Z",
      "location_count": 50,
      "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467844"
    }
  ]
}